{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:45:26Z","timestamp":1790829926810,"version":"4.1.0"},"reference-count":53,"publisher":"Impact Journals, LLC","issue":"68","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,12,22]]},"DOI":"10.18632\/oncotarget.22626","type":"journal-article","created":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T10:37:09Z","timestamp":1511433429000},"page":"112783-112796","source":"Crossref","is-referenced-by-count":95,"title":["Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells"],"prefix":"10.18632","volume":"8","author":[{"given":"Kevin G.","family":"Pinz","sequence":"first","affiliation":[{"name":"iCell Gene Therapeutics LLC, Research & Development Division, Long Island High Technology Incubator, Stony Brook, NY 11790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Yakaboski","sequence":"additional","affiliation":[{"name":"iCell Gene Therapeutics LLC, Research & Development Division, Long Island High Technology Incubator, Stony Brook, NY 11790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Jares","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stony Brook Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stony Brook Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia E.","family":"Firor","sequence":"additional","affiliation":[{"name":"iCell Gene Therapeutics LLC, Research & Development Division, Long Island High Technology Incubator, Stony Brook, NY 11790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin H.","family":"Chen","sequence":"additional","affiliation":[{"name":"iCell Gene Therapeutics LLC, Research & Development Division, Long Island High Technology Incubator, Stony Brook, NY 11790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Wada","sequence":"additional","affiliation":[{"name":"iCell Gene Therapeutics LLC, Research & Development Division, Long Island High Technology Incubator, Stony Brook, NY 11790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda","family":"Salman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Stony Brook Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tse","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, James Graham Brown Cancer Center, University of Louisville Health Sciences Center, Louisville, KY 40202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Hagag","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Stony Brook Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengshuo","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Stony Brook Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine Lai-Han","family":"Leung","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Jiang","sequence":"additional","affiliation":[{"name":"iCell Gene Therapeutics LLC, Research & Development Division, Long Island High Technology Incubator, Stony Brook, NY 11790, USA"},{"name":"State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupo","family":"Ma","sequence":"additional","affiliation":[{"name":"iCell Gene Therapeutics LLC, Research & Development Division, Long Island High Technology Incubator, Stony Brook, NY 11790, USA"},{"name":"State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau SAR, China"},{"name":"Department of Pathology, Stony Brook Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,11,22]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","article-title":"How I treat prolymphocytic leukemia","volume":"120","author":"Dearden","year":"2012","journal-title":"Blood"},{"key":"2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/imr.12243","article-title":"Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"263","author":"June","year":"2015","journal-title":"Immunol Rev"},{"key":"3","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ctrv.2014.08.001","article-title":"Therapeutic options in relapsed or refractory peripheral T-cell lymphoma","volume":"40","author":"Tilly","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"4","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Jagadeesh","year":"2014","journal-title":"Ann Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial","volume":"172","author":"Shustov","year":"2016","journal-title":"Br J Haematol"},{"key":"7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia","volume":"365","author":"June","year":"2011","journal-title":"N Engl J Med"},{"key":"8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1182\/blood.V122.21.69.69","article-title":"Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy","volume":"122","author":"Purdon","year":"2013","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood.V122.21.68.68","article-title":"Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","volume":"122","author":"Mackall","year":"2013","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood.V122.21.874.874","article-title":"Phase I Trial Of Autologous CD19-Targeted CAR-Modified T Cells As Consolidation After Purine Analog-Based First-Line Therapy In Patients With Previously Untreated CLL","volume":"122","author":"Brentjens","year":"2013","journal-title":"Blood"},{"key":"11","doi-asserted-by":"publisher","first-page":"56219","DOI":"10.18632\/oncotarget.11019","article-title":"Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies","volume":"7","author":"Ma","year":"2016","journal-title":"Oncotarget"},{"key":"12","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor","volume":"31","author":"Leung","year":"2017","journal-title":"Leukemia"},{"key":"13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.leu.2400877","article-title":"Biphasic expression of CD4 in acute myelocytic leukemia (AML) cells: AML of monocyte origin and hematopoietic precursor cell origin","volume":"12","author":"Kamada","year":"1998","journal-title":"Leukemia"},{"key":"14","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/1535370215584936","article-title":"From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy","volume":"240","author":"Ma","year":"2015","journal-title":"Exp Biol Med Maywood NJ"},{"key":"15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2249.1993.tb08176.x","article-title":"treatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees","volume":"93","author":"Rieber","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood.V87.3.893.bloodjournal873893","article-title":"Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody","volume":"87","author":"Levy","year":"1996","journal-title":"Blood"},{"key":"17","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","article-title":"Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma","volume":"109","author":"Lisby","year":"2007","journal-title":"Blood"},{"key":"18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1365-2141.2010.08298.x","article-title":"Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma","volume":"150","author":"Hagberg","year":"2010","journal-title":"Br J Haematol"},{"key":"19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1385\/MO:22:2:191","article-title":"Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4)","volume":"22","author":"Enblad","year":"2005","journal-title":"Med Oncol Northwood Lond Engl"},{"key":"20","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Ma","year":"2016","journal-title":"Leukemia"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00021","article-title":"Advantages and applications of CAR-expressing natural killer cells","volume":"6","author":"Koehl","year":"2015","journal-title":"Front Pharmacol"},{"key":"22","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1365-2567.2007.02573.x","article-title":"kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection","volume":"121","author":"Macallan","year":"2007","journal-title":"Immunology"},{"key":"23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/10430340460732463","article-title":"Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease","volume":"15","author":"Introna","year":"2004","journal-title":"Hum Gene Ther"},{"key":"24","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy","volume":"365","author":"Savoldo","year":"2011","journal-title":"N Engl J Med"},{"key":"25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.stem.2014.01.020","article-title":"Clonal tracking of rhesus macaque hematopoiesis highlights a distinct lineage origin for natural killer cells","volume":"14","author":"Chen","year":"2014","journal-title":"Cell Stem Cell"},{"key":"26","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3109\/14653249.2012.671519","article-title":"A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies","volume":"14","author":"Campana","year":"2012","journal-title":"Cytotherapy"},{"key":"27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/cgt.2009.61","article-title":"Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method","volume":"17","author":"Peshwa","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"28","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.jcyt.2014.01.064","article-title":"Anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer (NK) cells significantly mediate rituximab sensitive and resistant burkitt lymphoma (BL) regression and improve survival in human BL xenografted NSG mice","volume":"16","author":"Cairo","year":"2014","journal-title":"Cytotherapy"},{"key":"29","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1158\/1078-0432.CCR-08-2810","article-title":"2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells","volume":"15","author":"Rossig","year":"2009","journal-title":"Clin Cancer Res"},{"key":"30","doi-asserted-by":"publisher","first-page":"17481","DOI":"10.1073\/pnas.0804788105","article-title":"Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas","volume":"105","author":"Charo","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"31","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Bug","year":"2013","journal-title":"Cytotherapy"},{"key":"32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/2051-1426-2-S2-P24","article-title":"NK-92 cellular immunotherapy as an alternative to donor derived peripheral blood NK cells","volume":"2","author":"Klingemann","year":"2014","journal-title":"J Immunother Cancer"},{"key":"33","doi-asserted-by":"publisher","first-page":"e26527","DOI":"10.4161\/onci.26527","article-title":"Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity","volume":"2","author":"Klingemann","year":"2013","journal-title":"Oncoimmunology"},{"key":"34","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhanceandantitumor activity against human multiple myeloma","volume":"28","author":"Zhang","year":"2014","journal-title":"Leukemia"},{"key":"35","doi-asserted-by":"publisher","first-page":"iii44","DOI":"10.1093\/neuonc\/nou209.9","article-title":"ErbB2\/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma","volume":"16","author":"Seifried","year":"2014","journal-title":"Neuro-Oncol"},{"key":"36","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.leukres.2008.11.024","article-title":"Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells","volume":"33","author":"Klingemann","year":"2009","journal-title":"Leuk Res"},{"key":"37","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Hou","year":"2014","journal-title":"Mol Oncol"},{"key":"38","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/mt.2014.219","article-title":"Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2\/HER2-Specific Chimeric Antigen Receptor","volume":"23","author":"Jauch","year":"2015","journal-title":"Mol Ther"},{"key":"39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/cgt.2011.66","article-title":"Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor","volume":"19","author":"Cheung","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"40","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.4049\/jimmunol.0900447","article-title":"A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity","volume":"183","author":"Morgan","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"41","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood.V126.23.1534.1534","article-title":"Third Generation CD19-CAR T Cells for Relapsed and Refractory Lymphoma and Leukemia Report from the Swedish Phase I\/IIa Trial","volume":"126","author":"Loskog","year":"2015","journal-title":"Blood"},{"key":"42","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1128\/AAC.00942-08","article-title":"Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults","volume":"53","author":"Lewis","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"43","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1086\/380802","article-title":"Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1","volume":"189","author":"Shanahan","year":"2004","journal-title":"J Infect Dis"},{"key":"44","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Rosenberg","year":"2010","journal-title":"Blood"},{"key":"45","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy","volume":"17","author":"Grupp","year":"2009","journal-title":"Mol Ther"},{"key":"46","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1038\/cti.2014.11","article-title":"Adoptive T-cell therapy: adverse events and safety switches","volume":"3","author":"Tey","year":"2014","journal-title":"Clin Transl Immunol"},{"key":"47","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28147","article-title":"Are natural killer cells superior CAR drivers?","volume":"3","author":"Klingemann","year":"2014","journal-title":"Oncoimmunology"},{"key":"48","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1086\/315398","article-title":"Effect of HIV on thymic function before and after antiretroviral therapy in children","volume":"181","author":"Luzuriaga","year":"2000","journal-title":"J Infect Dis"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"20","author":"Cai","year":"2017","journal-title":"Leukemia"},{"key":"50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1365-2249.2002.01950.x","article-title":"Changes in thymus volume in adult HIV-infected patients under HAART: correlation with the T-cell repopulation","volume":"130","author":"Lissen","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"51","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.bbmt.2012.01.006","article-title":"Rapid thymic reconstitution following bone marrow transplantation in neonatal mice is VEGF-dependent","volume":"18","author":"Crooks","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"52","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1089\/15258160152509145","article-title":"Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92","volume":"10","author":"Seifried","year":"2001","journal-title":"J Hematother Stem Cell Res"},{"key":"53","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14653240802301872","article-title":"Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial","volume":"10","author":"Klingemann","year":"2008","journal-title":"Cytotherapy"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T18:47:33Z","timestamp":1596739653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,22]]},"references-count":53,"journal-issue":{"issue":"68","published-print":{"date-parts":[[2017,12,22]]}},"alternative-id":["22626","29348865"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.22626","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,22]]}}}